Do New Medicines Do More Harm Than Good? – Findings from 20 Years of NICE Decisions

Do New Medicines Do More Harm Than Good? – Findings from 20 Years of NICE Decisions #NICE #HealthEconomics #DrugPolicy #PharmaceuticalPolicy #MedicalResearch #EvidenceBasedMedicine #HealthPolicy #PublicHealth #DrugEvaluation #ClinicalEvidence #HealthcareEconomics #PopulationHealth #BiomedicalResearch #HealthcarePolicy #ConsiliumScientific #DrugEffectiveness Do newly approved medicines always improve population health? What if funding new drugs actually reduces overall health outcomes in a healthcare system? This seminar examines surprising findings from two decades of drug approval decisions. About This Video In this seminar, health policy researcher Huseyin Naci examines the population health impact of new medicines recommended by the National Institute for Health and Care Excellence in England between 2000 and 2020. Health systems constantly face difficult trade-offs when allocating limited resources, and decisions about drug funding can have far-reaching consequences. While new medicines can generate health benefits for individual patients, funding these treatments often requires diverting resources from other healthcare services. This creates opportunity costs where potential health gains elsewhere in the system may be lost. Using two decades of data, this research explores whether the overall population health gains from new medicines outweigh the health that may be displaced due to the reallocation of NHS resources. What You Will Learn ✅ How health systems evaluate the value of new medicines ✅ What does opportunity cost mean in healthcare funding decisions ✅ How NICE recommendations influence NHS drug coverage ✅ Why some new medicines may displace more health than they generate ✅ How health economists measure population-level health outcomes Main Topic of This Video This lecture focuses on the health economic consequences of funding new medicines within a publicly funded healthcare system. It examines how decisions by NICE affect population health and explores whether current evaluation frameworks accurately capture the true value of new drugs. Key Topics Covered in This Video NICE drug evaluation process in England Opportunity cost in healthcare spending Population health impact of new medicines Health technology assessment methods Cost-effectiveness thresholds in the NHS Why This Video Is Important Healthcare systems operate under limited budgets, meaning that funding one treatment may require reducing investment in another. Understanding the true impact of these decisions is essential for responsible health policy. This research highlights the difficult balance between providing access to innovative medicines and protecting overall population health. By examining long term data from NICE decisions, the study raises important questions about how healthcare systems evaluate drug value and allocate resources. These insights are critical for policymakers, researchers, and healthcare professionals working to ensure that new medicines deliver meaningful benefits without unintentionally harming broader public health outcomes. Timestamps 00:00 Introduction 02:30 Population Health Impact of New Medicines 08:15 NICE Decision Making and Opportunity Cost 15:40 Evaluating Health Gains and Health Losses 22:10 Trade Offs in Healthcare Resource Allocation 31:00 Policy Implications for Drug Funding 39:00 Audience Questions and Discussion nice drug evaluation, health economics research, opportunity cost healthcare, population health impact medicines, NHS drug policy analysis, health technology assessment methods, pharmaceutical policy research, cost effectiveness healthcare policy, drug funding decisions NHS, evidence-based medicine policy, healthcare resource allocation, clinical effectiveness evaluation, population health economics, pharmaceutical regulation policy, health system decision making 📲 STAY CONNECTED with Consilium Scientific X: @consiliumsci LinkedIn: LinkedIn: consilium-scientific Instagram: @consilium.scientific Substack: https://healthontrial.substack.com/ If this discussion was valuable, please LIKE, SUBSCRIBE, and SHARE this video to support research transparency and evidence-based healthcare. Comment below: Should healthcare systems reconsider how they evaluate the true impact of new medicines? ⚠️ IMPORTANT DISCLAIMER The information shared on this channel is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Viewers should consult qualified healthcare professionals for medical concerns or decisions. Consilium Scientific aims to promote research transparency and evidence-based discussion. Opinions expressed by speakers or guests are their own and do not necessarily reflect the official views of Consilium Scientific.